SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Fransen J, Moens HB, Speyer I, van Riel PL. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis 2005; 64: 12948.
  • 2
    Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52: 338190.
  • 3
    Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364: 2639.
  • 4
    Makinen H, Kautiainen H, Hannonen P, Mottonen T, Leirisalo-Repo M, Laasonen L, et al. Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis. J Rheumatol 2007; 34: 31621.
  • 5
    Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007; 66: 14439.
  • 6
    Choy EH, Khoshaba B, Cooper D, MacGregor A, Scott DL. Development and validation of a patient-based disease activity score in rheumatoid arthritis that can be used in clinical trials and routine practice. Arthritis Rheum 2008; 59: 1929.
  • 7
    Pincus T, Sokka T. Quantitative measures for assessing rheumatoid arthritis in clinical trials and clinical care. Best Pract Res Clin Rheumatol 2003; 17: 75381.
  • 8
    Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 448.
  • 9
    Schmajuk G, Schneeweiss S, Katz JN, Weinblatt ME, Setoguchi S, Avorn J, et al. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum 2007; 57: 92834.
  • 10
    Wolfe F, Michaud K. Resistance to changing therapy: discordance between RA activity and patients' treatment choices [abstract]. Arthritis Rheum 2006; 54 Suppl: S4256.
  • 11
    Creemers M, Fransen J, Welsing P, Kievit W, van Riel P. Assessment of the DAS28 in rheumatoid arthritis patients in daily clinical practice: is monitoring enough to reach low disease activity? [abstract]. Arthritis Rheum 2005; 52 Suppl: S1167.
  • 12
    Ryan M, Gerard K, Amya-Amaya M. Using discrete choice experiments to value health and health care. 1st ed. Houten (The Netherlands): Springer; 2008.
  • 13
    Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ 2000; 320: 15303.
  • 14
    Fraenkel L, Rabidou N, Dhar R. Are rheumatologists' treatment decisions influenced by patients' age? Rheumatology (Oxford) 2006; 45: 15557.
  • 15
    Howell J. Sawtooth Software research paper series: CBC/HB for beginners. 2009. URL: http://www.sawtoothsoftware.com/download/techpap/CBCHBbeginners.pdf.
  • 16
    Orme B. Sawtooth Software research paper series. Hierarchical Bayes: why all the attention? 2000. URL: http://www.sawtoothsoftware.com/download/techpap/hbwhy.pdf.
  • 17
    Sawtooth Software. Sawtooth Software research paper series: the CBC/HB system for hierarchical Bayes estimation version 5.0 technical paper. 2009. URL: http://www.sawtoothsoftware.com/download/techpap/hbtech.pdf.
  • 18
    Radovits BJ, Fransen J, Eijsbouts A, van Riel P, Laan RF. Missed opportunities in the treatment of elderly patients with rheumatoid arthritis. Rheumatology (Oxford) 2009; 48: 90610.
  • 19
    Radovits BJ, Kievit W, Fransen J, van der Laar MA, Jansen TL, van Riel PL, et al. Influence of age on the outcome of anti-TNFα therapy in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 14703.
  • 20
    Bathon JM, Fleischmann RM, van der Heijde D, Tesser JR, Peloso PM, Chon Y, et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol 2006; 33: 23443.
  • 21
    Schiff MH, Yu EB, Weinblatt ME, Moreland LW, Genovese MC, White B, et al. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies. Drugs Aging 2006; 23: 16778.
  • 22
    Genevay S, Finckh A, Ciurea A, Chamot AM, Kyburz D, Gabay C, for the Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis. Tolerance and effectiveness of anti–tumor necrosis factor α therapies in elderly patients with rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2007; 57: 67985.
  • 23
    Fleischmann R, Baumgartner SW, Weisman MH, Liu T, White B, Peloso P. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis 2006; 65: 37984.
  • 24
    Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001; 44: 200917.
  • 25
    Welsing PM, Landewe RB, van Riel PL, Boers M, van Gestel AM, van der Linden S, et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum 2004; 50: 208293.
  • 26
    Harrington JT. The uses of disease activity scoring and the physician global assessment of disease activity for managing rheumatoid arthritis in rheumatology practice. J Rheumatol 2009; 36: 9259.
  • 27
    Kievit W, Welsing PM, Adang EM, Eijsbouts AM, Krabbe PF, van Riel PL. Comment on the use of self-reporting instruments to assess patients with rheumatoid arthritis: the longitudinal association between the DAS28 and the VAS general health. Arthritis Rheum 2006; 55: 74550.
  • 28
    Wolfe F, Michaud K. Proposed metrics for the determination of rheumatoid arthritis outcome and treatment success and failure. J Rheumatol 2009; 36: 2733.
  • 29
    Yazici Y, Krasnokutsky S, Barnes JP, Hines PL, Wang J, Rosenblatt L. Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis. J Rheumatol 2009; 36: 90713.